Your browser doesn't support javascript.
loading
Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study.
Dobra, R; Elborn, J S; Madge, S; Allen, L; Boeri, M; Kee, F; Goundry, S; Purcell, T; Saunders, C; Davies, J C.
Affiliation
  • Dobra R; National Heart Lung Institute, Imperial College London, London, United Kingdom; Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield Trust, London, United Kingdom. Electronic address: r.dobra@rbht.nhs.uk.
  • Elborn JS; School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
  • Madge S; Department of Adult Cystic Fibrosis, Royal Brompton and Harefield Trust, London, United Kingdom.
  • Allen L; Clinical Trials Accelerator Platform, Cystic Fibrosis Trust, United Kingdom.
  • Boeri M; RTI Health Solutions, Health Preference Assessment, Belfast, United Kingdom.
  • Kee F; School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
  • Goundry S; Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Purcell T; Department of Adult Cystic Fibrosis, Royal Brompton and Harefield Trust, London, United Kingdom.
  • Saunders C; National Heart Lung Institute, Imperial College London, London, United Kingdom.
  • Davies JC; National Heart Lung Institute, Imperial College London, London, United Kingdom; Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield Trust, London, United Kingdom.
J Cyst Fibros ; 20(6): 986-993, 2021 11.
Article in En | MEDLINE | ID: mdl-33895096
ABSTRACT

BACKGROUND:

Making trials more patient-centred improves recruitment and retention, patient satisfaction and makes research accessible to a more representative population. We aimed to understand the factors that influence participation and engagement in clinical trials in cystic fibrosis (CF) trials to guide the rational design and delivery of patient-centred trials.

METHODS:

We used a Delphi process, supported by extensive literature review and 3 workshops, to determine which factors stakeholders think exert significant influence in participation and engagement in CF trials. Panellists were recruited from across the UK and the study was administered online.

RESULTS:

We had representation from 19 CF centres; 28 people with CF (pwCF), 26 parents and 30 healthcare professionals (HCPs). Panels were presented with a shortlist of 104 factors and asked which they thought influence participation and engagement in CF trials. After 3 iterations, 43 statements met consensus for pwCF, 48 for the parents and 69 for the HCPs.

CONCLUSIONS:

We identified many targets to make trials more patient-centred. Whilst some require an overhaul of trial delivery, many are relatively easy to implement. We outline a list of 'dos and don'ts' for sponsors and research teams including focus on good communication; recognise that lack of time is the greatest barrier to trial participation so minimise the frequency and length of visits; help participants fit trials around busy lives; remember trial participation can be a major life-event and support participants accordingly; and don't underestimate the impact of simple strategies e.g. on-site access to Wifi and cups of tea.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Clinical Trials as Topic / Delphi Technique / Cystic Fibrosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Cyst Fibros Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Clinical Trials as Topic / Delphi Technique / Cystic Fibrosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Cyst Fibros Year: 2021 Document type: Article